These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27142069)

  • 1. After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer.
    Nakamura S; Murakami N; Inaba K; Wakita A; Kobayashi K; Takahashi K; Okamoto H; Umezawa R; Morota M; Sumi M; Igaki H; Ito Y; Itami J
    BMC Cancer; 2016 May; 16():296. PubMed ID: 27142069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
    Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
    Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported Quality of Life After SBRT, LDR, and HDR Brachytherapy for Prostate Cancer: A Comparison of Outcomes.
    Paly JJ; Egleston BL; Wong JK; Burbure N; Sobczak ML; Hayes SB; Chen DYT; Horwitz EM; Hallman MA
    Am J Clin Oncol; 2021 Apr; 44(4):131-136. PubMed ID: 33577175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
    Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brachytherapy for Buccal Cancer: From Conventional Low Dose Rate (LDR) or Mold Technique to High Dose Rate Interstitial Brachytherapy (HDR-ISBT).
    Kotsuma T; Yamazaki H; Masui K; Yoshida K; Shimizutani K; Akiyama H; Murakami S; Isohashi F; Yoshioka Y; Ogawa K; Tanaka E
    Anticancer Res; 2017 Dec; 37(12):6887-6892. PubMed ID: 29187469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Image-Guided Intensity-Modulated Radiotherapy and Low-dose Rate Brachytherapy with or without External Beam Radiotherapy in Patients with Localized Prostate Cancer.
    Tsubokura T; Yamazaki H; Masui K; Sasaki N; Shimizu D; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Nishikawa T; Okabe H
    Sci Rep; 2018 Jul; 8(1):10538. PubMed ID: 30002393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer.
    Makino T; Nakashima K; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Kumano T; Mizokami A
    Anticancer Res; 2019 Jan; 39(1):477-486. PubMed ID: 30591498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer.
    Dhere VR; Fischer-Valuck BW; Goyal S; Liu Y; Morgan TM; Ghavidel E; Moghanaki DM; Hershatter BW; Patel PR; Jani AB; Godette KD; Rossi PJ; Patel SA
    Brachytherapy; 2021; 20(6):1130-1138. PubMed ID: 34417136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An age-corrected matched-pair study of erectile function in patients treated with dose-escalated adaptive image-guided intensity-modulated radiation therapy vs. high-dose-rate brachytherapy for prostate cancer.
    Marina O; Warner J; Ye H; Grills IS; Shah C; Wallace M; Gustafson GS; Brabbins DS; Martinez AA; Krauss DJ
    Brachytherapy; 2014; 13(2):163-8. PubMed ID: 24295963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer.
    Kakimoto N; Inoue T; Inoue T; Murakami S; Furukawa S; Yoshida K; Yoshioka Y; Yamazaki H; Tanaka E; Shimizutani K
    Radiother Oncol; 2003 Aug; 68(2):123-8. PubMed ID: 12972306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer.
    Shah C; Lanni TB; Ghilezan MI; Gustafson GS; Marvin KS; Ye H; Vicini FA; Martinez AA
    Brachytherapy; 2012; 11(6):441-5. PubMed ID: 22728157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer.
    Ghadjar P; Matzinger O; Isaak B; Behrensmeier F; Stroux A; Rentsch CA; Thalmann GN; Aebersold DM
    Radiother Oncol; 2009 May; 91(2):237-42. PubMed ID: 19167121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy.
    Hermesse J; Biver S; Jansen N; Lenaerts E; De Patoul N; Vynckier S; Coucke P; Scalliet P; Nickers P
    Strahlenther Onkol; 2009 Nov; 185(11):736-42. PubMed ID: 19899007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetric and radiobiological comparison of volumetric modulated arc therapy, high-dose rate brachytherapy, and low-dose rate permanent seeds implant for localized prostate cancer.
    Yang R; Zhao N; Liao A; Wang H; Qu A
    Med Dosim; 2016; 41(3):236-41. PubMed ID: 27400663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
    Hermesse J; Biver S; Jansen N; Lenaerts E; Nickers P
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):269-76. PubMed ID: 19775833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Asian patients with localized prostate cancer treated with combined intensity modulated radiation therapy (IMRT) and high dose rate (HDR) brachytherapy: A single institution experience.
    Ng IWS; Tey JCS; Soon YY; Tseng MSF; Chen D; Lim KHC
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e386-e391. PubMed ID: 29171166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
    Martinez AA; Demanes J; Vargas C; Schour L; Ghilezan M; Gustafson GS
    Am J Clin Oncol; 2010 Oct; 33(5):481-8. PubMed ID: 19952715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.